Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.(SUPN)

Top Performer Top performer •Today's top pick Today’s top pick
upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
5-STAR RATING
STRONG BUY
BUY for 1 day
PROFIT SINCE LAST BUY
0.00%
LAST CLOSE
$29.72
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SUPN

11/13/2026: SUPN (5-star) is a STRONG-BUY. BUY for 1 day. Simulated Profits (0.00%). Updated daily EoD!

Supernus Pharmaceuticals is a specialty company focused on developing and commercializing branded drugs for epilepsy and ADHD. The firm has a leading position in niche CNS segments, relying on its proficiency in creating differentiated, extended-release formulations. The company's primary growth opportunity centers on the commercial expansion of Qelbree, while its main risks involve pending patent cliffs for legacy epilepsy drugs and ongoing competition from generic manufacturers. The stock may interest growth-oriented investors looking for CNS exposure, though they should be prepared for significant volatility. Investors should monitor Qelbree’s quarterly sales growth and outcomes from legal challenges related to its patent portfolio.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company's growth depends on the successful adoption of newer products like Qelbree to offset declining legacy revenues.
Momentum investorWeak fitMomentum is inconsistent as the stock often reacts sharply to patent news and drug launch data.
Value investorMixed fitThe stock may appear undervalued on certain metrics, but business quality risks and patent cliffs complicate the valuation thesis.
Dividend investorWeak fitSupernus does not pay a dividend, making it unsuitable for income-focused portfolios.
Low-risk investorWeak fitSmall-cap pharmaceutical stocks carry inherent regulatory and clinical trial risks that create significant volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is susceptible to large price swings based on clinical data releases and litigation outcomes.
Valuation riskMediumValuation is sensitive to long-term projections of Qelbree revenue and the competitive landscape.
Competition risk (generic/branded)HighGeneric competition for legacy products poses a persistent threat to margins and revenue stability.
Business qualityMediumThe business relies on a few key products, creating a concentration risk in its revenue stream.
Dividend incomeLow / noneNo dividends are provided, so there is no income component to the total return.
Execution riskMedium / highSuccess depends heavily on marketing execution for Qelbree and R&D efficiency.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 6.17B USD
Price to earnings Ratio -
1Y Target Price 54.14
Price to earnings Ratio -
1Y Target Price 54.14
Volume (30-day avg) 3.5M shares
Beta 1.13
52 Weeks Range 21.48 - 33.22
Updated Date 11/14/2026
52 Weeks Range 21.48 - 33.22
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.76

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 141.07%
Avg. Invested days 39
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SUPN receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
SUPN has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+10400.0%) and solid profitability (net margin 16.9%) are partially offset by weak cash generation (FCF margin -7.6%), moderate revenue growth (+4.3%), modest insider ownership of 2.65%.

Financial Health Rating

★★★★★
SUPN's financial health is supported by solid profitability, including gross margin of 80.1% and operating margin of 21.4%. Cash strength is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is SUPN's strongest growth driver at +10400.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+4.3%, moderate) and free-cash-flow growth (-1980.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 59.7% and approximately 55.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.65% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 16.06%
Millennium Management LLC 6.62%
Dimensional Fund Advisors, Inc. 6.56%
Vanguard Portfolio Management, LLC 5.68%
Armistice Capital, LLC 4.54%

Unit Economics (Per $1K Revenue)

★★★★★
SUPN generates approximately $801 of gross profit, $214 of operating income, and $-76 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Negative free cash flow explains the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 12.13%

Quantitative Style Profile

★★★★★
SUPN has a high-quality, liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
CNS PharmaceuticalsSales of branded drugs for epilepsy, migraine, and ADHD, primarily in the US market.The company generates revenue by selling specialized, patented prescription drugs to patients managing brain-related conditions.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-29
When Before Market
Estimate 0.34
Actual 0.78

Profitability

Profit Margin 32.75%
Operating Margin (TTM) 46.94%

Management Effectiveness

Return on Assets (TTM) 29.34%
Return on Equity (TTM) -4.15%

Valuation

Trailing PE -
Forward PE 20.16
Enterprise Value 5.85B
Price to Sales(TTM) 4.49
Enterprise Value 5.85B
Price to Sales(TTM) 4.49
Enterprise Value to Revenue 6.76
Enterprise Value to EBITDA 96.3
Shares Outstanding 207.72M
Shares Floating 114.74M
Shares Outstanding 207.72M
Shares Floating 114.74M
Percent Insiders 2.65
Percent Institutions 59.73

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.